泰莫索利米德的安全性评估:来自FAERS数据库的现实不良事件分析
Yu Liu1, Lan Ma1,2, Xiaojia Fu1,2
1Department of Neurosurgery, Affiliated Huaian Hospital of Xuzhou Medical University, Huaian, China.
Frontiers in pharmacology
|August 22, 2025
概括
这项研究分析了对temozolomide (TMZ) 副作用的现实数据,发现血液毒性,肺栓塞和机会性感染的重大风险. 加强监测和预防对于改善患者在质瘤治疗中的安全至关重要.
科学领域:
- 药物监督管理
- 癌症学
- 药物安全
背景情况:
- 泰莫佐洛米德 (TMZ) 是用于质母细胞瘤和形细胞瘤的关键化疗剂,通常与放射治疗一起使用.
- 尽管TMZ有效,但与许多不良反应 (AE) 相关,需要进行彻底的安全评估.
- 了解TMZ的实际安全性对于优化神经瘤患者护理至关重要.
研究的目的:
- 使用FDA不良事件报告系统 (FAERS) 数据库进行回顾性药监测研究,评估与temozolomide相关的不良事件.
- 在大量现实患者中识别和量化与temozolomide相关的安全信号.
- 突出改善治疗TMZ患者的临床监测和风险管理策略的潜在领域.
主要方法:
- 对FAERS数据库进行了回顾性分析,其中包括超过4800万份报告.
- 使用病例/非病例方法,使用统计方法,包括报告概率 (ROR) 和比例报告比率 (PRR) 来检测AE信号.
- 采用贝叶斯信任传播神经网络 (BCPNN) 和多项玛-波森构造器 (MGPS) 等用于信号检测的算法.
主要成果:
- 从48,766,547个FAERS报告中确定了13,608个与temozolomide相关的不良事件.
- 血液毒性,特别是"血液和淋巴系统疾病" (ROR 5. 94) 是最突出的信号,血小板数量下降 (ROR 8. 61) 和斑块 (ROR 9. 87) 是值得注意的.
- 有意义的突发事件包括肺栓塞 (ROR 4. 96),肺炎 (Pneumocystis jirovecii) (ROR 7. 09) 和神经毒性事件如发作 (ROR 6. 19).
结论:
- 泰莫佐洛米德与严重的血液毒性,血栓塞栓事件和机会性感染的实际风险有关.
- 在确定需要进一步调查的新安全信号的同时证实了预期的毒性,例如骨髓抑制.
- 建议加强血液监测,血栓预防和肺囊预防,以减轻与TMZ相关的风险,并优化其在质瘤患者中的治疗益处.
相关概念视频
Pharmacovigilance
989
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
989
Teratogenicity
2.7K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.7K
Drug Regulation
1.8K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.8K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
174
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
174
Hazard Ratio
243
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
243


